[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Rhea-AI Filing Summary

Daniel P. O'Day, Chairman & CEO of Gilead Sciences (GILD), reported sales of common stock on 09/29/2025 under a pre-established Rule 10b5-1 trading plan adopted February 28, 2025. The Form 4 shows two sale transactions: 8,039 shares sold at prices reported in a range around $110.97–$111.92 and 1,961 shares sold at prices reported in a range around $112.00–$112.55. After these transactions the reporting person beneficially owned 591,203 shares. The filing was submitted under Section 16 and executed by power of attorney. The disclosure states that full per-price breakdowns are available on request.

Positive

• Trades executed under a Rule 10b5-1 plan, indicating pre-established, non-discretionary sales.
• Reporting person retains substantial beneficial ownership after the reported dispositions (591,203 shares reported).

Negative

• Insider sold 10,000 shares in two transactions, representing a reduction in direct holdings.
• Detailed per-price allocation not disclosed in the Form; available only upon request per the explanatory note.

Insights

Financial Analyst

TL;DR: Insider sales of GILD shares were executed under a Rule 10b5-1 plan, indicating pre-scheduled dispositions rather than ad hoc trades.

The reported sales total 10,000 shares executed on 09/29/2025 in two tranches with reported price ranges provided in the explanation. Because the transactions were made pursuant to a 10b5-1 plan adopted on February 28, 2025, the trades are consistent with a pre-authorized schedule that can reduce concerns about opportunistic timing. The report shows continued substantial beneficial ownership—591,203 shares—after the sales. For investors, the filing is routine disclosure of insider liquidity; it does not provide information about company performance or strategy.

Corporate Governance Expert

TL;DR: Use of a documented 10b5-1 plan is good governance practice for orderly insider sales and regulatory compliance.

The Form 4 identifies Daniel P. O'Day as both Director and Chairman & CEO and discloses sales executed under a 10b5-1 plan adopted 02/28/2025, which supports an argument for procedural compliance and reduced insider trading risk. The filing was signed via power of attorney, as noted in the signature block. The disclosure that detailed per-price trade allocations will be furnished on request is standard, but stakeholders may request that breakdown for full transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2025		S(1)		8,039	D	$111.4703(2)	593,164	D
Common Stock	09/29/2025		S(1)		1,961	D	$112.4193(3)	591,203	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

2. Sale prices reported for the transactions reported here range from $110.97 to $111.92. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

3. Sale prices reported for the transactions reported here range from $112.00 to $112.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Daniel P. O'Day	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions does the GILD Form 4 by Daniel P. O'Day report?

The Form 4 reports two sales on 09/29/2025: 8,039 shares and 1,961 shares sold under a Rule 10b5-1 trading plan.

Was the sale executed under a pre-established trading plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 02/28/2025.

How many GILD shares did the reporting person own after these transactions?

The Form 4 shows the reporting person beneficially owned 591,203 shares following the reported sales.

What price information is provided for the sales?

The Form lists price ranges: $110.97–$111.92 for one sale and $112.00–$112.55 for the other; detailed per-price allocations are available on request.

Who signed the Form 4 filing for Daniel P. O'Day?

The Form 4 was signed by Edward S. Son by power of attorney on behalf of Daniel P. O'Day.